Citi lowered the firm’s price target on Ultragenyx (RARE) to $45 from $50 and keeps a Buy rating on the shares post the earnings report. The firm cites the “uneven” ordering patterns for Crysvita in Latin America and Ultragenyx’s new guidance for 2026 for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Earnings Call Balances Growth With Risk
- Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures
- Ultragenyx price target lowered to $49 from $75 at TD Cowen
- Ultragenyx price target lowered to $61 from $71 at Goldman Sachs
- Ultragenyx price target lowered to $40 from $47 at Baird